tbuckley/cabot-search huggingface dataset:
Elderly Cirrhotic Patients with Pre-Dementia Mild Cognitive Impairment and Minimal Hepatic Encephalopathy Have a Distinct Cognitive and Brain MR Profile
Authors: V. Ahluwahlia, J. Wade, F. Moeller, J. Steinberg, M. White, A. Unser, A. Fagan, D. Ganapathy, R. Sterling, R.T. Stravitz, S. Matherly, V. Luketic, A. Sanyal, M. Siddiqui, P. Puri, M. Fuchs, D. Heuman, J.S.S. Bajaj
Journal: Journal of Hepatology (2016)
LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1
Authors: Ming Sun, Fengqi Nie, Yunfei Wang, Zhihong Zhang, Jiakai Hou, Dandan He, Min Xie, Lin Xu, Wei De, Zhaoxia Wang, Jun Wang
Journal: Cancer Research (2016)

Long noncoding RNAs (lncRNA) have been implicated in human cancer but their mechanisms of action are mainly undocumented. In this study, we investigated lncRNA alterations that contribute to gastric cancer through an analysis of The Cancer Genome Atlas RNA sequencing data and other publicly available microarray data. Here we report the gastric cancer-associated lncRNA HOXA11-AS as a key regulator of gastric cancer development and progression. Patients with high HOXA11-AS expression had a shorter survival and poorer prognosis. In vitro and in vivo assays of HOXA11-AS alterations revealed a complex integrated phenotype affecting cell growth, migration, invasion, and apoptosis. Strikingly, high-throughput sequencing analysis after HOXA11-AS silencing highlighted alterations in cell proliferation and cell-cell adhesion pathways. Mechanistically, EZH2 along with the histone demethylase LSD1 or DNMT1 were recruited by HOXA11-AS, which functioned as a scaffold. HOXA11-AS also functioned as a molecular sponge for miR-1297, antagonizing its ability to repress EZH2 protein translation. In addition, we found that E2F1 was involved in HOXA11-AS activation in gastric cancer cells. Taken together, our findings support a model in which the EZH2/HOXA11-AS/LSD1 complex and HOXA11-AS/miR-1297/EZH2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression, suggesting new therapeutic directions in gastric cancer. Cancer Res; 76(21); 6299-310. ©2016 AACR.
Hepatitis E in Haematological Patients in Europe: A Multicentre Study
Authors: J. Von Felden, L. Alric, P. Schnitzler, D. Bettinger, J.M. Peron, H. Wedemeyer, U. Spengler, S. Schlabe, C. Hoener zu Siederdissen, J. Cornelissen, M.T. Giordani, G. Par, C. Aitken, R. Thimme, A.W. Lohse, R.A. de Man, S. Pischke, V. Mallet
Journal: Journal of Hepatology (2016)
A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents
Authors: Guillermo Garcia-Manero, Selina M Luger, Stuart Goldberg, Jessica K Altman, Martha Arellano, Meir Wetzler, Karen Seiter, Judy Chiao, Hagop M Kantarjian
Journal: Blood (2013)
Platelet Count and Liver Stiffness Measurement to Exclude High-Risk Gastroesophageal Varices in Patients with HCV-Cirrhosis. A Multicentric Study
Authors: M. Puigvehí, M.-C. Londoño, R.M. Morillas, M. Miquel, A. Gallego, S. Lens, Z. Mariño, M. Vergara, S. Lorente, X. Torras, R. Planas, R. Solà, J.A. Carrión
Journal: Journal of Hepatology (2016)
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C. Badoux, Steliana Calin, James M. Reuben, Susan M. O'Brien, Steven M. Kornblau, Hagop M. Kantarjian, Bang-Ning Lee, Alessandra Ferrajoli
Journal: Blood (2012)
Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
Authors: Katrina Wilcox Hagberg, Hozefa A Divan, Rebecca Persson, J Curtis Nickel, Susan S Jick
Journal: BMJ (2016)

To estimate the risk of erectile dysfunction in men who used 5-α reductase inhibitors to treat benign prostatic hyperplasia or alopecia. Cohort studies with nested case-control analyses. UK Clinical Practice Research Datalink. Two populations of men free of risk factors for erectile dysfunction and other sexual dysfunction or its treatment: men aged 40 or more with benign prostatic hyperplasia who received a prescription for a 5-α reductase inhibitor (finasteride or dutasteride) or α blocker, or both, and men aged 18-59 with alopecia. In the benign prostatic hyperplasia study, exposures were classified as 5-α reductase inhibitors only, 5-α reductase inhibitors+α blockers, or α blockers only. In the alopecia study, exposures were finasteride 1 mg or no treatment. Cases were men with a diagnosis of erectile dysfunction or treatment (procedure or prescription for a phosphodiesterase type 5 inhibitor) during follow-up. We calculated incidence rates and adjusted incidence rate ratios with 95% confidence intervals. We also conducted nested case-control analyses to control for major confounders, and calculated adjusted odds ratios with 95% confidence intervals. In the population with benign prostatic hyperplasia (n=71 849), the risk of erectile dysfunction was not increased with use of 5-α reductase inhibitors only (incidence rate ratio 0.92, 95% confidence interval 0.85 to 0.99; odds ratio 0.94, 95% confidence interval 0.85 to 1.03) or 5-α reductase inhibitors+α blocker (1.09, 0.99 to 1.21, 0.92; 0.80 to 1.06) compared with α blockers only, and remained null regardless of number of prescriptions or timing of use. The risk of erectile dysfunction increased with longer duration of benign prostatic hyperplasia, regardless of exposure. For the alopecia population (n=12 346), the risk of erectile dysfunction was not increased for users of finasteride 1 mg compared with unexposed men with alopecia (1.03, 0.73 to 1.44; 0.95, 0.64 to 1.41). 5-α reductase inhibitors do not seem to significantly increase the risk of incident erectile dysfunction, regardless of indication for use. Risk of erectile dysfunction increased with longer duration of benign prostatic hyperplasia.
Oral candidosis in the oncology department of the University Hospital in Pisa: prospective observational study
Authors: E. Frediani, A. Vietina, S. Fambrini, P. Carfagno, C. Pardossi, I. Buonamini, L. Gambini, M. Giorgi, C. Losoni, P. Pacchini, P. Pozzi, L. Minutella, G. De Luca, D. Rossini, A. Romanini
Journal: Annals of Oncology (2015)
Excessive β-Blockade With Timolol Eye Drops
Authors: Jeffrey W. Kalenak
Journal: JAMA (1996)

To the Editor.  —Dr Edeki and colleagues1provide evidence that appears to support their conclusion that an individual's debrisoquin phenotype is an important determinant of β-blockade following timolol eyedrops, and metabolism of timolol is inhibited and β-blockade increased by coadministration of oral quinidine. But they failed to discuss two troublesome issues that may affect the internal and external validity of their study.  First, the authors failed to report the methods they used to select the sample size of 13. In general, randomized controlled trials begin with a calculation to predetermine sample size before recruitment is started. The authors are no doubt aware that these methods include selection of a desired power (typically 0.80 or 0.90), a reasonable estimate of treatment effect (drug vs placebo) in units of the main outcome measure, an estimate of pooled variance, and a level of significance, 1—α (the authors accepted α ≤.05). They cited
Salvage treatment in metastatic breast cancer (MBC) with weekly paclitaxel (P) plus biweekly bevacizumab (B).
Authors: A. Polyzos, K. Kalbakis, S. Giassas, A. Kalykaki, N. K. Vardakis, V. Bozionelou, E. S. Saloustros, E. Kontopodis, D. Mavroudis, V. Georgoulias
Journal: Journal of Clinical Oncology (2010)

e11503 Background: The dose and schedule of paclitaxel administration have been evolving during the last years. Weekly paclitaxel has shown improved results compared to a 3-weekly schedule. In addition, the combination of B+P has significant activity in MBC. Methods: Pretreated patients with MBC received weekly P (90mg/m2 days 1, 8, 15) and B (10mg/m2 q2w) every 28 days. This was the second-line chemotherapy for 30% and the third-line for 70%. The majority of patients (67%) has already received docetaxel. Results: A total of 40 patients were registered and evaluated. Median age: 61 (32-80); postmenopausal: 80%; baseline ECOG<2 80% of patients. Metastatic sites were lung (45%), nodes (60%), liver (47%), pleura (35%), bone (47%). Two patients (5%) achieved CR, 10 (25%) PR (ORR 30%; 95% CI 15,8-44,2) and 10 (25%) SD; the median FU was 7.6 (range, 2.5-14.0) mo, the median time to progression 4.8 mo (95% CI 1.8-7.75). The median survival was 13.6 mo (95% CI 11.6-15.5) and the probability of 1-year survival (61.3%). Main grade 3-4 toxicities were: neutropenia (32.5%) and febrile neutropenia (7.5%). A total of 170 cycles were administered (median: 4 cycles/patient). Conclusions: The PB regimen is well tolerated and active in pretreated mainly postmenopausal women and could be an effective option as salvage therapy even for patients exposed to taxanes during prior treatments. No significant financial relationships to disclose.
Real Life Experience in Treating Chronic Hepatitis C with Direct Acting Antivirals: Genotyping and Subtype Matter
Authors: C. Ramière, M. Maynard, K. Hartig-Lavie, F. Bailly, V. Virlogeux, F. Zoulim, P. Miailhes, L. Cotte, O. Guillaud, J. Dumortier, J. Ritter, P. André, C. Scholtès
Journal: Journal of Hepatology (2016)
“Othello Hypothesis” Involved in the Development of Ravs Tolerant to NS5A Inhibitors in Patients with Genotype 1B HCV Infection
Authors: Y. Uchida, J.-I. Kouyama, K. Naiki, K. Sugawara, M. Inao, Y. Imai, N. Nakayama, S. Mochida
Journal: Journal of Hepatology (2016)
Benefit of Sebelipase Alfa in Children and Adults with Lysosomal Acid Lipase Deficiency Based on Analysis of Efficacy by Baseline Alanine Aminotransferase Level
Authors: F. Abel, J.-B. Arnoux, M. Kostyleva, A. Tylki-Szymańska, M. Friedman, A. Consuelo, R. Tripuraneni
Journal: Journal of Hepatology (2016)
Preservation of epithelial cell barrier function and muted inflammation in resistance to allergic rhinoconjunctivitis from house dust mite challenge
Authors: Sunil K. Ahuja, Muthu Saravanan Manoharan, Nathan L. Harper, Fabio Jimenez, Benjamin D. Hobson, Hernan Martinez, Puraskar Ingale, Ya-Guang Liu, Andrew Carrillo, Zheng Lou, Dean L. Kellog, Seema S. Ahuja, Cynthia G. Rather, Robert E. Esch, Daniel A. Ramirez, Robert A. Clark, Kari Nadeau, Charles P. Andrews, Robert L. Jacobs, Weijing He
Journal: Journal of Allergy and Clinical Immunology (2016)
The retrospective study of single-agent capecitabine in the maintenance treatment of recurrent and metastatic breast cancer.
Authors: H. Huang, Z. Jiang, T. Wang, S. Zhang, L. Bian, Y. Cao, S. Wu, S. Song
Journal: Journal of Clinical Oncology (2010)

e11512 Background: Metastatic breast cancer ( MBC) is incurable. Although chemotherapy is important for MBC, optimal duration of chemotherapy for MBC is debatable. Maintenance therapy in NSCLC indicated survival benefit. However, similar therapy in MBC showed controversial results. In the study we evaluated maintenance chemotherapy of capecitabine in MBC. Methods: MBC patients receiving capecitabine-based therapy enrolled in the retrospective study if evaluated as CR/PR/SD. The patients continued capecitabine as maintenance therapy until PD or unacceptable toxicities. The maintenance treatment was administrated as: oral capecitabine 1,000 mg/ m2 twice daily on days 1 to 14 followed by a 7-day rest period of each 3-week cycle. The characteristics of patients were listed in the Table. Results: From September 2002 to September 2009, 64 eligible patients enrolled in the study with median age 50 years (range 26-71 years). The best responses after combination therapy were 2 (3.13%) CR, 29 (45.31%) PR, and 33 (51.56%) SD. Median duration of combination was 3 months (range 1-7.5 months). After maintenance therapy 32.2% of the patients obtained clinical benefit. 81.36% preserved the previous response. Median TTP of maintenance therapy was 4 months (range 1-20 months) . The most common toxicity in maintenance therapy was HFS (n=34, 53.13%) with 14.06% (n= 9) of patients suffered grades 3 HFS. Most toxicities were moderate and manageable. Conclusions: Capecitabine may be an optimal maintenance treatment in patients with MBC after effective combined therapy including capecitabine with well tolerance. Patient characteristics Characteristics Patient No. % Menopause status Premenopause 36 56.25% Postmenopause 28 43.75% ER/PR status Positive 41 64.06% Negative 23 35.94% HER2 status Positive 5 7.81% Negative 55 85.94% Unknown 4 6.25% Metastatic sites Liver 21 32.81% Lung 23 35.94% Brain 1 1.56% Bone 33 51.56% Soft tissue 23 35.94% Others 8 12.5% No. of tumor sites 1 25 39.06% 2 22 34.38% ≥3 17 26.56% Setting of study treatment First-line 29 45.31% Second-line 25 39.06% More than second-line 10 15.63% Capecitabine-based combined regimen TX 40 62.5% NX 24 37.5% No significant financial relationships to disclose.
Proteinkinase C-β Inhibitors Mitigate Microenvironment-Mediated Survival Of CLL Cells and Sensitise Malignant B Cells To Cytotoxic Drugs
Authors: Gloria Lutzny, Zhoulei Li, Madlen Oelsner, Jolanta Slawska, Thomas Kocher, Alexander Egle, Christian Peschel, Ulrich Keller, Ingo Ringshausen
Journal: Blood (2013)
Inhibition of cytokine-induced MCP-1 production in human airway smooth muscle cells and epithelial cells by glucocorticoids but not by phosphodiesterase inhibitors
Authors: JL Pype, LJ Dupont, Patricia Menten, W Put, Jozef Van Damme, MG Demedts, Geert Verleden
Journal: American Journal of Respiratory and Critical Care Medicine (1999)
A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease
Authors: Armand Mekontso Dessap, France Pirenne, Keyvan Razazi, Stéphane Moutereau, Shariq Abid, Christian Brun‐Buisson, Bernard Maitre, Marc Michel, Frederic Galacteros, Pablo Bartolucci, Anoosha Habibi
Journal: American Journal of Hematology (2016)

Diagnosis of delayed hemolytic transfusion reactions (DHTR), one of the most dreaded complications of transfusion in patients with sickle cell disease (SCD), is challenging and not straightforward. Current diagnostic approaches are complex and not consensual; they are based on assessment of hemoglobin (Hb) drop and enhanced hemolysis, features also seen during classical vaso-occlusive events. In this observational study, we tested the hypothesis that the rate of decline in HbA after an index transfusion is a surrogate marker for the destruction of transfused RBC, which could be used diagnostically. We examined 421 transfusion episodes (in 128 patients of a French referral center for SCD) for which an Hb electrophoresis was obtained within 1 week following an index transfusion and repeated within 2 months (before a subsequent scheduled transfusion or during an acute complication). Chart review found DHTR to be present in 26 cases (6.2%), absent in 389 cases (92.4%), and possible in six cases (1.4%). As expected, DHTR was associated with accelerated hemolysis (increased serum bilirubin and lactic dehydrogenase concentrations) and a decline in total Hb as compared to the early post-transfusion value. However, the decline in HbA concentration appeared more effective in segregating between patients without DHTR and others. We propose a diagnostic nomogram for DHTR based on Hb A as a biologic marker of the survival of transfused RBCs. Am. J. Hematol. 91:1181-1184, 2016. © 2016 Wiley Periodicals, Inc.
Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC).
Authors: M. Cotto, J. Toro, V. Carlo, R. Vaquer, O. A. Pavia, M. Bruno, E. Rivera, M. M. Echenique, V. Negron, F. Cabanillas
Journal: Journal of Clinical Oncology (2010)

564 Background: Pathologic CR or near CR after NAC is associated with excellent clinical outcome. However, some patients fail to respond, thus receiving unnecessary NAC that could lead to progression prior to surgery. Early identification of drug resistance can prompt discontinuation or early modification of ineffective NAC. We compared predictive value of an early 18FDG-PET/CT scan after first NAC course and MRI after 4 courses of NAC. We then evaluated their correlation with pathologic response. Methods: Pts with localized invasive BC ≥2 cm were eligible. MRI and 18FDG-PET/CT scan were performed at baseline. PET was repeated two weeks after course 1 of anthracycline-based NAC. SUVmax were compared with baseline. We measured the % drop in SUVmax after course #1 NAC and % reduction in size of largest diameter by MRI after course #4. We used the M. D. Anderson Residual Cancer Burden (RCB) tool (JCO 25:4414, 2007), which calculates the degree of pathologic response using a formula to measure the amount of residual cancer after surgery following NAC. This generates a number that is a continuous variable starting from 0. RCB 0- 1.36 corresponds to RCB category 0-1 (excellent response, 5-yr FFS = 95%), while RCB 1.37-3.27 are RCB 2 (good response, 80% FFS) and those >3.27 are RCB 3 (poor response, 40% FFS). Results: 50 pts were entered; 37 have already undergone surgery. ER+/Her2neg = 21, Her2+ = 11, triple neg = 5. Median values for: age = 49 (32- 75), largest diameter = 3.3 (2-6.5), histologic grade = 2, stage = 2A. After NAC, median RCB value for >5% SUVmax drop = 0.93 while for drop ≤5%= 3.5 (p = 0.000003). Conclusions: PET has a highly significant predictive value for RCB and is capable of predicting response earlier and better than MRI. % SUVmax drop RCB 0-1 RCB 2 RCB 3 Total p value >5% 18 (64%) 7 (25%) 3 (11%) 28 0.0001 ≤5% 0 2* (22%) 7 (78%) 9 Response by MRI CR+PR 13 (65%) 4 (20%) 3 (15%) 20 0.06 SD+PD 4 (25%) 5 (31%) 7 (44%) 16 * In pt #29, RCB2 response reflected results of a switch in NAC regimen after fourth course due to lack of response to primary therapy; if this pt is excluded RCB3 = 7/8 (88%). Positive predictive value (PPV) of PET = 89%, neg pred value (NPV) = 78% (88% if pt #29 excluded). For MRI, PPV and NPV = 85% and 44%. No significant financial relationships to disclose.
A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer
Authors: Joseph Vijai, Sabine Topka, Danylo Villano, Vignesh Ravichandran, Kara N. Maxwell, Ann Maria, Tinu Thomas, Pragna Gaddam, Anne Lincoln, Sarah Kazzaz, Brandon Wenz, Shai Carmi, Kasmintan A. Schrader, Steven N. Hart, Steve M. Lipkin, Susan L. Neuhausen, Michael F. Walsh, Liying Zhang, Flavio Lejbkowicz, Hedy Rennert, Zsofia K. Stadler, Mark Robson, Jeffrey N. Weitzel, Susan Domchek, Mark J. Daly, Fergus J. Couch, Katherine L. Nathanson, Larry Norton, Gad Rennert, Kenneth Offit
Journal: Cancer Discovery (2016)

Abstract Known gene mutations account for approximately 50% of the hereditary risk for breast cancer. Moderate and low penetrance variants, discovered by genomic approaches, account for an as-yet-unknown proportion of the remaining heritability. A truncating mutation c.325C&amp;gt;T:p.Arg109* (R109X) in the ATP-dependent helicase ERCC3 was observed recurrently among exomes sequenced in BRCA wild-type, breast cancer–affected individuals of Ashkenazi Jewish ancestry. Modeling of the mutation in ERCC3-deficient or CRISPR/Cas9-edited cell lines showed a consistent pattern of reduced expression of the protein and concomitant hypomorphic functionality when challenged with UVC exposure or treatment with the DNA alkylating agent IlludinS. Overexpressing the mutant protein in ERCC3-deficient cells only partially rescued their DNA repair–deficient phenotype. Comparison of frequency of this recurrent mutation in over 6,500 chromosomes of breast cancer cases and 6,800 Ashkenazi controls showed significant association with breast cancer risk (ORBC = 1.53, ORER+ = 1.73), particularly for the estrogen receptor–positive subset (P &amp;lt; 0.007). Significance: A functionally significant recurrent ERCC3 mutation increased the risk for breast cancer in a genetic isolate. Mutated cell lines showed lower survival after in vitro exposure to DNA-damaging agents. Thus, similar to tumors arising in the background of homologous repair defects, mutations in nucleotide excision repair genes such as ERCC3 could constitute potential therapeutic targets in a subset of hereditary breast cancers. Cancer Discov; 6(11); 1267–75. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1197
Intracoronary transplantation of labelled mesenchymal stem cells post myocardial infarction is associated with increased angiogenesis but fails to enhance functional recovery
Authors: C Dubois, P Jans, W Streb, Peter Pokreisz, Glenn Marsboom, Hilde Gillijns, Desire Collen, Frans Van de Werf, Stefan Janssens
Journal: Journal of the American College of Cardiology (2005)
CDKN2 Gene Deletion As Poor Prognosis Predictor Involving in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients
Authors: Yuling Li, Na Xu, Xuan Zhou, Jixian Huang, Lin Li, Qisi Lu, Ziyuan Lu, Bolin He, Chengyun Pan, Qifa Liu, Liu Xiaoli
Journal: Blood (2015)
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)
Authors: F Rojo, J Tabernero, Eric Van Cutsem, A Ohtsu, J Albanell, W Koizumi, M Peeters, S Averbuch, N Gallagher, J Baselga
Journal: Journal of Clinical Oncology (2003)
Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.
Authors: Hugues de Lavallade, Jamshid S. Khorashad, Marco Bua, Dragana Milojkovic, Eduardo Olavarria, Alistair Reid, Jaspal S. Kaeda, John M. Goldman, Jane F. Apperley, David Marin
Journal: Blood (2007)
Impaired Thymic Negative Selection Causes Chronic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation.
Authors: Yukimi Sakoda, Daigo Hashimoto, Kengo Takeuchi, Shoji Asakura, Koichi Akashi, Mitsune Tanimoto, Mine Harada, Takanori Teshima
Journal: Blood (2005)
Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score
Authors: P. Tandon, R. Reddy, J. O’Leary, G. Garcia-Tsao, F. Wong, S. Biggins, B. Maliakkal, M. Fallon, R. Subramanian, P. Thuluvath, P. Kamath, L. Thacker, J. Bajaj
Journal: Journal of Hepatology (2016)
CMV-Specific T-Cells Are More Effective Than WT-1-Specific T-Cells in Eradicating Clonogenic Tumor Cells Co-Expressing CMVpp65 and WT-1 in-Vivo and Both Types of T-Cells Are Functionally Augmented in the Presence of IL-15/IL-15Rα
Authors: Aisha Hasan, Dana Bakalar, Annamalai Selvakumar, Gloria C Koo, Ekaterina Doubrovina, Tzu-Yun Kuo, Richard J. O'Reilly
Journal: Blood (2011)